Skip to main content

Articles

Page 26 of 27

  1. The objective of this study was to describe the longitudinal cognitive outcome in Alzheimer's disease (AD) and analyze factors that affect the outcome, including the impact of different cholinesterase inhibito...

    Authors: Carina Wattmo, Åsa K Wallin, Elisabet Londos and Lennart Minthon
    Citation: Alzheimer's Research & Therapy 2011 3:23
  2. Progressive language impairment is among the primary components of cognitive decline in Alzheimer's disease (AD). Because expressive and receptive language help to maintain emotional connections to caregivers ...

    Authors: Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun and Yikang Xu
    Citation: Alzheimer's Research & Therapy 2011 3:22
  3. The pathology of Alzheimer's disease (AD) is characterized by amyloid plaques (aggregates of amyloid-β (Aβ)) and neurofibrillary tangles (aggregates of tau) and is accompanied by mitochondrial dysfunction, but...

    Authors: Anne Eckert, Karen Schmitt and Jürgen Götz
    Citation: Alzheimer's Research & Therapy 2011 3:15
  4. Neuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of the inflammatory network and participate in the regulation of the blood-brain barrier's perme...

    Authors: François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy and Olivier Hermine
    Citation: Alzheimer's Research & Therapy 2011 3:16
  5. The clinical and scientific study of dementia in adults with Down syndrome led to the development of the amyloid hypothesis as a fundamental concept in Alzheimer's disease pathogenesis. The journey started wit...

    Authors: Robyn A Wallace and Arthur J Dalton
    Citation: Alzheimer's Research & Therapy 2011 3:13
  6. APOE is the strongest risk gene for sporadic Alzheimer's disease (AD) so far. Recent genome wide association studies found links for sporadic AD with CLU and CR1 involved in Aβ clearance, and PICALM affecting int...

    Authors: Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo and Pekka J Karhunen
    Citation: Alzheimer's Research & Therapy 2011 3:12
  7. Current theory suggests that β-amyloid accumulation may be an early step in the cascade that leads to cognitive impairment in Alzheimer's disease. β-Amyloid targeted positron emission tomography (PET) imaging ...

    Authors: Michael J Pontecorvo and Mark A Mintun
    Citation: Alzheimer's Research & Therapy 2011 3:11
  8. Novel compounds with potential to attenuate or stop the progression of Alzheimer's disease (AD) from its presymptomatic stage to dementia are being tested in man. The study design commonly used is the long-ter...

    Authors: René Spiegel, Manfred Berres, André R Miserez and Andreas U Monsch
    Citation: Alzheimer's Research & Therapy 2011 3:9
  9. Alzheimer's disease (AD) is widely recognized as a serious public health problem and heavy financial burden. Currently, there is no treatment that can delay or stop the progressive brain damage in AD. Recently...

    Authors: Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley and Li-Ru Zhao
    Citation: Alzheimer's Research & Therapy 2011 3:8
  10. There are more than 36 million people in the US over the age of 65, and all of them are impacted by the cognitive decline and brain atrophy associated with normal aging and dementia-causing conditions like Alz...

    Authors: Neill R Graff-Radford
    Citation: Alzheimer's Research & Therapy 2011 3:6
  11. Levels of cerebrospinal fluid (CSF) β-amyloid (Aβ) and Tau proteins change in Alzheimer's disease (AD). We tested if the relationships of these biomarkers with cognitive impairment are linear or non-linear.

    Authors: Jonathan H Williams, Gordon K Wilcock, Jeffrey Seeburger, Aimee Dallob, Omar Laterza, William Potter and A David Smith
    Citation: Alzheimer's Research & Therapy 2011 3:5
  12. Alzheimer disease (AD) is a devastating neurodegenerative disease affecting 1 in 68 in the population. An arbitrary cutoff 65 years as the age of onset to distinguish between early- and late-onset AD has been ...

    Authors: Kinga Szigeti and Rachelle S Doody
    Citation: Alzheimer's Research & Therapy 2011 3:4
  13. Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and mole...

    Authors: Randall J Bateman, Paul S Aisen, Bart De Strooper, Nick C Fox, Cynthia A Lemere, John M Ringman, Stephen Salloway, Reisa A Sperling, Manfred Windisch and Chengjie Xiong
    Citation: Alzheimer's Research & Therapy 2011 3:1
  14. Inhibition of gamma-secretase presents a direct target for lowering Aβ production in the brain as a therapy for Alzheimer's disease (AD). However, gamma-secretase is known to process multiple substrates in add...

    Authors: Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui…
    Citation: Alzheimer's Research & Therapy 2010 2:36
  15. While Alzheimer's disease researchers continue to debate the underlying cause(s) of the disease, most agree that a diverse, multi-target approach to treatment will be necessary. To this end, the Alzheimer's Dr...

    Authors: Linda H Lee, Diana W Shineman and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2010 2:33
  16. In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-b...

    Authors: Henrik Zetterberg, Niklas Mattsson, Kaj Blennow and Bob Olsson
    Citation: Alzheimer's Research & Therapy 2010 2:32
  17. There is a great need for quick tests that identify treatment response in Alzheimer's disease (AD) to determine who benefits from the treatment. In this study, A Quick Test of cognitive speed (AQT) was compare...

    Authors: Sebastian Palmqvist, Lennart Minthon, Carina Wattmo, Elisabet Londos and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2010 2:29
  18. With the advent of advances in biomarker detection and neuropsychological measurement, prospects have improved for identifying and tracking the progression of Alzheimer's disease (AD) from its earliest stages ...

    Authors: Larry G Brooks and David A Loewenstein
    Citation: Alzheimer's Research & Therapy 2010 2:28
  19. Structural brain deficits have been repeatedly linked to body mass index and obesity, which itself is controlled by the effects of a number of independent genetic loci. One of the most consistently replicated ...

    Authors: Lars Bertram and Hauke Heekeren
    Citation: Alzheimers Res Ther 2010 2:27
  20. Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this s...

    Authors: Roy W Jones
    Citation: Alzheimer's Research & Therapy 2010 2:25
  21. Atrophy measured on structural magnetic resonance imaging (sMRI) is a powerful biomarker of the stage and intensity of the neurodegenerative aspect of Alzheimer's disease (AD) pathology. In this review, we wil...

    Authors: Prashanthi Vemuri and Clifford R Jack Jr
    Citation: Alzheimer's Research & Therapy 2010 2:23
  22. The present review of Alzheimer's disease (AD) rating scales aims to outline the need for a new rating scale to be used in routine clinical practice for long-term medical care of AD patients. An ideal scale would...

    Authors: Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad and Frank Tennigkeit
    Citation: Alzheimer's Research & Therapy 2010 2:24
  23. Since the reformulation of the amyloid cascade hypothesis to focus on oligomeric aggregates of amyloid beta as the prime toxic species causing Alzheimer's disease, many researchers refocused on detecting a spe...

    Authors: Kerensa Broersen, Frederic Rousseau and Joost Schymkowitz
    Citation: Alzheimer's Research & Therapy 2010 2:12
  24. Recently, it has become clear that head trauma can lead to a progressive neurodegeneration known as chronic traumatic encephalopathy. Although the medical literature also implicates head trauma as a risk facto...

    Authors: Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski and Ann C McKee
    Citation: Alzheimer's Research & Therapy 2010 2:18
  25. Recent advances in biomarkers for Alzheimer's disease (AD) now allow the visualization of one of the hallmark pathologies of AD in vivo, and combination biomarker profiles can now approximate the diagnostic accur...

    Authors: Reisa Sperling and Keith Johnson
    Citation: Alzheimer's Research & Therapy 2010 2:17
  26. Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer's disease (AD). In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and tiss...

    Authors: Erik Stomrud, Maria Björkqvist, Sabina Janciauskiene, Lennart Minthon and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2010 2:20
  27. Evidence from clinical samples and geographically limited population studies suggests that vascular health, diabetes and apolipoprotein ε4 (APOE) are associated with dementia.

    Authors: David J Llewellyn, Iain A Lang, Fiona E Matthews, Brenda L Plassman, Mary AM Rogers, Lewis B Morgenstern, Gwenith G Fisher, Mohammed U Kabeto and Kenneth M Langa
    Citation: Alzheimer's Research & Therapy 2010 2:19